A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

Martin Farlow, Ravi Anand, John Messina, Richard Hartman, Jeffrey Veach

Research output: Contribution to journalArticle

285 Citations (Scopus)

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalEuropean Neurology
Volume44
Issue number4
StatePublished - 2000

Fingerprint

Rivastigmine
Alzheimer Disease
Placebos
Cholinesterase Inhibitors
Cognition

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitor
  • Clinical trial
  • Rivastigmine

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. / Farlow, Martin; Anand, Ravi; Messina, John; Hartman, Richard; Veach, Jeffrey.

In: European Neurology, Vol. 44, No. 4, 2000, p. 236-241.

Research output: Contribution to journalArticle

Farlow, Martin ; Anand, Ravi ; Messina, John ; Hartman, Richard ; Veach, Jeffrey. / A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. In: European Neurology. 2000 ; Vol. 44, No. 4. pp. 236-241.
@article{c4064a68392143ad91a514edd927d2c5,
title = "A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease",
abstract = "The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon{\circledR}), in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "Alzheimer's disease, Cholinesterase inhibitor, Clinical trial, Rivastigmine",
author = "Martin Farlow and Ravi Anand and John Messina and Richard Hartman and Jeffrey Veach",
year = "2000",
language = "English",
volume = "44",
pages = "236--241",
journal = "European Neurology",
issn = "0014-3022",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease

AU - Farlow, Martin

AU - Anand, Ravi

AU - Messina, John

AU - Hartman, Richard

AU - Veach, Jeffrey

PY - 2000

Y1 - 2000

N2 - The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright (C) 2000 S. Karger AG, Basel.

AB - The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6-12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo. Copyright (C) 2000 S. Karger AG, Basel.

KW - Alzheimer's disease

KW - Cholinesterase inhibitor

KW - Clinical trial

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=0033679259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033679259&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 236

EP - 241

JO - European Neurology

JF - European Neurology

SN - 0014-3022

IS - 4

ER -